Sacituzumab govitecan in metastatic triple negative breast cancer (TNBC): Four design features in the ASCENT trial potentially favored the experimental arm-Reference-Cited by-同舟云学术

Sacituzumab govitecan in metastatic triple negative breast cancer (TNBC): Four design features in the ASCENT trial potentially favored the experimental arm

Published:2022-01 Issue:1 Volume:15 Page:101248
ISSN:1936-5233
Container-title:Translational Oncology
language:en
Short-container-title:Translational Oncology

Author:

Olivier Timothee,Prasad Vinay

Funder

Arnold Ventures

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference15 articles.

1. Sacituzumab govitecan in metastatic triple-negative breast cancer;Bardia;N. Engl. J. Med.,2021

2. Characteristics of oncology clinical trials: insights from a systematic analysis of ClinicalTrials.gov;Hirsch;JAMA Intern. Med.,2013

3. Association between risk-of-bias assessments and results of randomized trials in cochrane reviews: the ROBES meta-epidemiologic study;Savović;Am. J. Epidemiol.,2018

4. Overestimation of the effect size in group sequential trials;Zhang;Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.,2012

5. Randomized trials stopped early for benefit: a systematic review;Montori;JAMA,2005

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Opportunities and Challenges in the Development of Antibody-Drug Conjugate for Triple-Negative Breast Cancer: The Diverse Choices and Changing Needs;World Journal of Oncology;2024-08

2. Current Status and Future Perspectives of Antibody–Drug Conjugates in Hormone Receptor-Positive Breast Cancer;Cancers;2024-05-08

3. Review of recent preclinical and clinical research on ligand-targeted liposomes as delivery systems in triple negative breast cancer therapy;Journal of Liposome Research;2024-03-23

4. Unveiling the Immune Microenvironment’s Role in Breast Cancer: A Glimpse into Promising Frontiers;International Journal of Molecular Sciences;2023-10-18

5. Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers;Cancers;2023-03-19